Denali Therapeutics Inc. (DNLI) Total liabilities 2017–2025
Denali Therapeutics Inc. (DNLI) total liabilities at each fiscal year-end, per SEC filings.
$131.1MFY2025 · since FY2017: $20.9M → $131.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $131.1M | -9.3% |
| FY2024 | $144.5M | +17.5% |
| FY2023 | $123.0M | -70.6% |
| FY2022 | $417.8M | -5.4% |
| FY2021 | $441.9M | -2.6% |
| FY2020 | $453.7M | +186.6% |
| FY2019 | $158.3M | +37.5% |
| FY2018 | $115.1M | +450.2% |
| FY2017 | $20.9M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice